BioTech To Initiate Clinical Trial For Shban Antiviral Hand Sanitizer

BioTech has contracted to start conducting independent clinical testing of its patented Shban Antiviral Hand Sanitizer Solution, to prove it kills the H1N1 (Swine) Influenza A virus in compliance with FDA and EPA standards.

BioTech reported that the Shban Solution had clinically proven its anti-viral properties and had topically killed the Avian Influenza virus. Significantly, Shban was proven non-toxic with no cytotoxicity observed on the MDCK cell line after treatment.

Shban is protected under US Letters of Patent 5514808, 5574050, 5679711 and 5585391, and pending international patents. Currently, it is sold as a 3 oz Shban Go Anywhere Hand Atomizer Spray Bottle, that complies with TSA carry-on travel regulations.